UBS maintains Envista Holdings at Neutral, raises price target to $29 from $27
UBS kept its Neutral rating on Envista Holdings but raised its price target to $29 from $27, suggesting a 16.2% upside from the Nov 5 close of $24.96. Recent analyst price targets for the company range from $26 to $32.
How this was made

The 30-second read
Why it matters
The new $29 target narrows the upside range and could attract short‑term interest.
Market read
A modest analyst upgrade for a micro‑cap; limited broader market effect.
What to watch
Potential headwinds from supply‑chain constraints are not addressed in the note.
Background
UBS analyst coverage of Envista Holdings includes recent target ranges of $26‑$32.
Ticker impact
UBS raised its price target on Envista Holdings to $29 from $27, indicating a fresh bullish analyst view.
likely modest buying pressure as investors price in the higher target
Target raise is a new piece of information but the magnitude is small and the company is a micro‑cap, limiting market impact.
Market effects
Minimal; the change reflects a slight shift in sentiment toward the medical‑device sector.
None
None
Counterpoint
The target raise may be premature if upcoming earnings miss expectations.
Key entities
- CompanyEnvista Holdings
Medical‑device manufacturer (ticker NVST).
- AnalystUBS
Investment bank providing the price target update.

